Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

A still from the "Rromantasy" commercial (Organon) The ad ends with a final nod to the genre, with the claim that Nexplanon is “over 99% effective, no matter the fantasy.” Organon pledges $30M ...

OGN BREAKING NEWS: Organon & Co. Stock Plummets 27% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NYSE:OGN) Leading securities law firm Bleichmar Fonti & Auld LLP ...

We recently published a list of These 10 Firms Are On Fire Today. In this article, we are going to take a look at where Organon & Co.’s (NYSE:OGN) stands against other stocks that surged yesterday.

Organon saw significant volatility last month with a 30% decline in its share price, coinciding with the company's announcement of decreased earnings and a reduction in its dividend payout.

NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors concerning the ...

Organon & Co. (NYSE:OGN), a prominent player in the healthcare sector, has been garnering attention from analysts due to its diverse product portfolio and strategic market positioning. The company ...

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks ...

GLOBAL healthcare company Organon recently hosted a forum titled "Women's Health Unveiled: Insights into Hormonal Shifts and Unplanned Pregnancies", shedding light on two often-overlooked yet critical ...

Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25 ...